Taiwan Approvals Open Next Stage of HARMONIC Trial for LP-300 in EGFR-Mutant NSCLC
LTRN is trading near its 52-week low of $0.838 (13% above the low) on elevated volume (2.1× avg).
Summary
Lantern Pharma received Taiwan TFDA and IRB approvals to open Part 2 of its Phase 2 HARMONIC trial for LP-300 in never-smoker, EGFR-mutant NSCLC. The amended protocol limits enrollment to patients with the EGFR exon 21 L858R mutation and extends LP-300 dosing from 6 to 8 cycles. Preliminary data show L858R patients completing 6 cycles had a median PFS of 8.9 months (n=9) versus 8.3 months for all L858R patients (n=16). The company also received US central IRB approval and is activating sites. This follows the Nasdaq delisting notice on October 1 and the $4M registered direct offering closed September 30, highlighting the company's need for clinical progress to address its going concern warning. The Taiwan approval expands the trial into a region with high EGFR mutation prevalence and could accelerate enrollment and partnering discussions.
At the time of this announcement, LTRN was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $0.84 to $4.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.